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Abstract 
Breast Cancer is the most common cancer among women worldwide with an estimated 
more than one million new cases every year, and it is the leading cancer-related cause of 
death among women. In Palestine, breast cancer is the most common malignancy in total 
population and the most common adult female malignancy according to the Cancer 
Registry centers (CRC) and Palestinian Ministry of Health (MOH). 
Activation induced cystidine deaminase (AID) is a member of APOBEC family of 
cystidine deaminase which deaminate cytosine in DNA leading to uracil. AID is an 
essential enzyme normally expressed in B cells. AID enzyme is necessary in diversifying 
the immune repertoire by two main processes; the first one is Class Switch Recombination 
(CSR), the second process is Somatic Hypermutation (SHM) which allows the immune 
system to adapt its response to any threats during the lifetime of an organism. Aberrant 
expression of AID causes genomic instability and induces mutations in multiple genes by 
favoring chromosome translocations and point mutations in both B and non-B cells, 
thereby stimulating cancer formation. AID expression has been reported in numerous 
cancers of non-B-cell origin, including breast, prostate, stomach, liver, and lung cancer. 
This study aims to screen the expression of AID protein in tissue sections of breast cancer 
in patients from Palestine and to determine the correlation between AID protein expression 
and the clinico-pathological data of these patients. To achieve this, paraffin blocks of 69 
breast cancer with their clinico-pathological data were collected retrospectively, between 
years (2009-2013) from the pathology department of Beit Jala Hospital. The expression 
levels of AID protein were examined in these cases by Immunohistochemistry (IHC) 
analysis.  
Our results showed an aberrant AID expression in 26.1% (18 of 69) of the breast cancer 
cases. No statistical correlation was observed between AID protein expression and clinico-
pathological data of the patients such as age, tumor grade and tumor stage (p>0.05). Our 
study is the first one that examines AID protein expression protein in breast cancer tissue 
samples in Palestine and in the world. In conclusion, our study showed aberrant expression 
of AID protein in Palestinian breast cancer patients, and this study will shed the light on 
the cancer research in Palestine. 
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Chapter One: Introduction 
 
1.1. Breast Cancer: 
Cancer has always been a big challenge to human health; not only it reduces the life quality 
but also increases mortality. Breast cancer (BC) is the most common cancer among women 
worldwide and the second most common cause of cancer related mortality in women due 
to recurrence and metastasis (Limame et al., 2014).  Breast cancer is a heterogeneous 
malignant proliferation of epithelial cells lining the milk ducts (Liu et al., 2015). During 
the last decade, research has focused on the molecular biology of this disease. All cancer 
types including breast cancer involve genetic alterations that lead to loss of function in 
tumor suppressor genes and/or gain of function in oncogenes (Eroles et al., 2011). 
 
1.1.1 Epidemiology of Breast Cancer: 
BC is the most common cancer among women worldwide with an estimated 1.38 million 
new cases diagnosed in 2008 (Ferlay et al., 2010). 
In Palestine, BC is the most common cancer with an incidence rate of 16.9 % from all 
reported cancer cases. BC is the most abundant in females (Abdeen, 2006), while colon 
cancer is the second (9.9%) from all reported cancers. Stomach cancer was in third place 
among females with rate (9.0%) of the all reported cases as shown in figure 1 (Ministry of 
Health, PHIC, Health Annual Report Palestine, 2014). 
 
 
Figure 1: Most Common Cancer Cases among females in West Bank, Palestine, 2011. 
(Ministry of Health, Palestinian Health Information Center PHIC, Health Status in 
Palestine, 2011) 
As for mortality rates, the most common cancer mortality in Palestine is bronchus and lung 
cancer (15.4%) in males. Among females breast cancer was the first leading cause of death 
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(21.1%) with a mortality rate of 5.2 per 100.000 females. (Abdeen, 2006; Ministry of 
Health Palestinian Health Information Center PHIC, 2002). 
 
1.1.2 Risk Factors of Breast Cancer 
Breast cancer is a multifactorial disease; many factors influence the occurrence of BC. The 
major risk factor is gender. Although BC affects both males and females, the incidence for 
women is much higher; females are at 100 fold higher risk than males (Kreiter et al., 
2014). Breast cancer incidence increases with age; the older the woman, the higher her 
risk, doubling about every 10 years until the menopause. It is rare before the age of 25 
years old, and increasing between the ages of 30-49 and after 50years old. Family history 
increases breast cancer risk, women with first degree relatives having the disease like 
(mother, sister or daughter) have double the risk to get BC. Moreover, genetic 
predisposition has an important role as 15% of breast cancer patients report family history 
of breast and ovarian cancer. Gene defects affect breast cancer risk. For example, BRCA1 
and BRCA2 genes are the most significant genes associating strongly with breast cancer 
risk. Mutated BRCA1 and BRCA2 genes affect biological functions including DNA repair. 
Other gene mutations may increase the breast cancer risk like: ATM, P53, CHEK2, PTEN, 
CDH1, STK11. Life style factors affect the breast cancer risk like taking birth control pills, 
hormonal therapy after menopause, age at menopause, breastfeeding, obesity, alcohol 
drinking, smoking, physical activity and radiation exposure (McPherson et al., 2000; Shah 
et al., 2014; Howell et al., 2014; Yip et al., 2014). 
 
1.1.3 Types of Breast Cancer 
According to the American Cancer Society most breast cancer cases are epithelial in 
origin, and are called carcinomas which arise from the epithelial cells that line breast ducts 
and lobules. Other types called Sarcoma which starts in the muscle or fat cells or 
connective tissues. Breast tissue is made up of ducts and lobules so breast cancer is 
classified depending on its histological appearance into ductal and lobular carcinomas as 
shown in figure 2. 
The most common types of breast cancer are named according to the parts of the breast in 
which they start: 
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In situ Ductal Carcinoma: 
Found in the early stages of breast cancer, it is treatable since it is not invasive, but if 
undetected or treated it can start to spread to other parts of the breast. 
Invasive Ductal Carcinoma (IDC): 
Invasive ductal carcinoma is the most common type of breast cancer, also called 
"infiltrative ductal carcinoma", in this type the cancer cells formed in the milk ducts and 
start to spread into other parts of the breast or to other organs. 
Lobular Carcinoma: 
 Begins in the lobes, or glands which produce milk in the breast. The lobes are located 
deeper inside the breast, under the ducts. About 8% of breast cancers are lobular. If the 
cancer is LCIS (lobular carcinoma in situ) that means the cancer is limited within the lobe 
and has not spread. 
There are other types like Inflammatory Breast cancer which is the least common but 
usually invasive and most aggressive, and Metastatic breast cancer when cancer cells start 
to spread to body organs such as lungs, bones, liver and brain (Bombonati and Sgroi, 2011) 
Other histological types of BC are rare and include mucinous, tubular, comedo, 
inflammatory, medullary, and papillary carcinoma. These types of breast cancer also differ 
in their clinical and tumor characteristics (Li et al., 2005) 
 
                Figure2: Breast Cancer Types. (Breast Cancer Care Organization) 
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1.1.4 Stages of Breast Cancer: 
There is a system of categorizing cancer into stages, based on three factors. The staging 
system most commonly used is the TNM which means (Tumor size, Node involvement, 
Metastasis) system. It is suggested by the American Joint Committee of Cancer (AJCC). 
TNM staging system is classified according to the primary tumor characteristics (T1-T4), 
the involvement of lymph nodes (N0-N3) and the presence or absence of metastasis (M1-
M0) as shown in the figure 3 below. 
 
Table 1 : TNM staging of Breast Cancer adopted from AJCC. 
 
1.1.5 Signs and Symptoms of Breast Cancer: 
According to the American cancer society the most common sign of breast cancer is the 
lump, usually detected on a screening mammogram before it can be felt by the woman. 
Other symptoms include changes in the breast like thickening, swelling, skin irritation and 
nipple abnormalities such as changing position, shape or rash around the nipple. Late signs 
appears when cancer grows or spreads to other parts of the body like bone pain, nausea, 
headache, weight loss, and cough.  
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1.1.6 Diagnosis of Breast Cancer: 
Early diagnosis can lead to successful treatment of breast cancer. Molecular imaging is the 
most powerful technique in clinical diagnosis of breast cancer (Alcantara et al., 2014). BC 
can be detected using the followed tests: 
1- Physical examination is very important, to detect skin changes such as; dimpling, 
erythema, nipple changes, asymmetry and obvious masses (Shah et al., 2014). 
2- Diagnostic imaging have central role in the diagnosis, treatment, and staging of patients 
with breast cancer. Recently mammogram is the most common method for BC 
diagnosis, it is used to produce fine detail images for the breast to detect early breast 
cancer, it has been developed over the past years to be able to use lower doses of 
radiation (Esserman et al., 2002). 
3- Ultrasound complement mammogram is a very common diagnostic tool in young 
women who have low risk of breast cancer; also it is the first diagnostic technique in 
pregnant and breastfeeding women (Alcantara et al., 2014). It is useful for identifying 
suspicious areas to be biopsied to confirm the diagnosis of breast cancer (Yamauchi et 
al., 2012). Recently used in BC screening for women > 40 years old. 
4- Magnetic resonance imaging (MRI). It may reveal a mass, architectural distortion, or 
calcifications in the breast (Yamauchi et al., 2012). It uses magnetic fields to measure 
the tumor size and how much the tumor has grown after a woman has been diagnosed 
with BC, the MRI sensitivity of invasive ductal carcinoma is nearly 100%. Breast MRI 
is useful in some specific situations, including; obese women, women with dense 
breasts and for cancers that are invasive and adjacent to the chest wall, to evaluate 
tumor extension and muscle involvement if that will help determine surgical approach. 
(Li et al., 2014). 
5- Surgical tests like biopsy which is the removal of small amount of breast tissue for 
examination under a microscope and analyzed by a pathologist can make definite 
diagnosis. It is used as traditional diagnosis for impalpable breast cancer, and the 
results help to guide treatment recommendations. (Liberman et al., 1996). 
 
After diagnosis the patients will have one of the following BC types: 
 Endocrine receptor-positive (estrogen or progesterone receptors) 
 HER2-positive. Human epidermal growth factor receptor-2. 
 Triple positive: positive for estrogen receptors, progesterone receptors, and HER2 
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 Triple negative: not positive for estrogen receptors, progesterone receptors, and HER2. 
 
1.1.7 Treatment of Breast Cancer: 
Breast Cancer is potentially curable if detected in the early stages. The treatment goal is to 
control the cancer locally and prevent its spread (Cardonick, 2014). Historically, single-
modality treatment to cure BC was not successful, the majority of patients developed 
recurrent or metastatic disease within two years. Therefore, combinations of adjuvant 
systemic chemotherapy, surgery, and radiation therapy have led to an improved prognosis 
(Yamauchi et al., 2012 ; Yip et al., 2014). 
The appropriate adjuvant therapy is determined by many factors like tumor size, grade, 
measures of proliferation, presence of lymphovascular invasion and human epidermal 
growth factor receptor 2 (HER-2) overexpression (Cianfrocca and Gradishar, 2005). 
 Surgery is an option that should always be considered regardless age of the patient 
because it has been shown to offer advantages in terms of survival and local disease 
control (Swaminathan et al., 2012). 
Endocrine therapy reduces the recurrence and mortality for hormone receptor positive 
patients. Radiation helps to get rid of loco-original microscopic disease in the breast, chest 
wall, skin and lymph nodes, it is used also to treat metastatic breast cancer that has spread 
to other areas like bones or brain (Rampurwala et al., 2014). 
 Two main adjuvant therapy modalities are cytotoxic chemotherapy and endocrine therapy 
(hormone receptor blocking therapy). Both adjuvant treatment modalities improve the 
overall survival in hormone receptor positive breast cancer patients (Westbrook and 
Stearns, 2013 ; Miller et al., 2014).  
 
1.1.8 Molecular Markers of Breast Cancer: 
Molecular markers are important tools for understanding patient clinical outcome and to 
ensure that cancer patients receive optimal treatment and to determine the future therapy 
plans. Most of the molecular markers have been both prognostic and of great predictive 
value (Taneja et al., 2010).The most common classical molecular markers used for BC 
screening and diagnosis are receptors which are proteins that help cells communicate with 
the outside. In breast cancer, if one of these receptors is overproduced it will trigger breast 
cells to grow and divide rapidly, which eventually leads to the development of a tumor or 
cancerous growth.    
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Hormone receptor: Estrogen receptor (ER) and progesterone receptor (PR) are strong 
predictive factors for response to endocrine therapy, they are assessed by 
immunohistochemistry. About 70-80% of all breast cancers are ER-positive and 60-65% 
are PR –positive (Weigel and Dowsett, 2010; Shah et al., 2014). 
Human epidermal growth factor receptor-2 (HER-2): The oncogene HER2 was first 
identified to be an indicator of patient’s prognosis. HER2 overproduction stimulate breast 
cancer cells to grow and divide rapidly leading to tumor growth as shown in figure 3 
(Fitzgibbons et al., 2000; Taneja et al., 2010). 
 HER2 is a predictive marker that predicts the response to certain therapies which target 
the HER-2/neu receptor. Patients with overexpression of HER2 (HER2 positive), 
unfortunately are more likely to suffer from relapse and tend to have a worse overall 
survival (Fitzgibbons et al., 2000; Taneja et al., 2010). 
 
 
Figure 3: HER2 overexpression in Breast Cancer (WordPress.com) 
 
Most breast cancers have one or more of these receptors overexpressed. However one type, 
called triple negative breast cancer does not have any of them. Triple negative breast 
cancers seem to be more difficult to treat and have a higher chance of recurrence (Phipps et 
al., 2011). 
Ki-67: Nuclear antigen proliferative marker, common as prognostic marker for early stage 
breast cancer patients, because it plays an important role in cell proliferation. Ki-67 
overexpression in more than 20-50% of the cells indicates that breast cancer patients are at 
high risk of recurrent disease. (Esteva and Hortobagyi, 2004; Taneja et al., 2010). Ki-67 
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used as prognostic factor provides useful information for the therapeutic decisions in breast 
cancer patients (Luporsi et al., 2012).  
 
1.1.9 Breast Cancer Molecular Heterogeneity 
Breast cancers exhibit tumor heterogeneity; it is reflected in the wide morphological and 
molecular variation, with a spectrum of histological features and molecular pathological 
markers that are useful in predicting clinical outcome and determining the appropriate 
treatment plan (Esserman et al., 2011). 
The heterogeneity of cancer cells introduces significant challenges in designing effective 
treatment strategies to yield higher efficacy therapeutic approaches; Hormonal receptor 
status; Estrogen receptor (ER)/Progesterone receptor (PR) positivity defines which tumor 
can be targetable by hormonal therapy. Likewise (HER2) amplification or overexpression 
determines if the tumor will be targetable with HER2 antagonists. Tumors that are negative 
for ER, PR and HER2 (Triple Negative) are not amenable to these targeted therapies, and 
often related to poor prognosis (Kwei et al., 2010). 
 
1.1.10 Genetic Alterations of Breast Cancer: 
Genetic background plays an important role in tumor susceptibility, because the major 
cause of all types of cancer is genetic alterations. Many genes contribute in breast cancer 
development when they are genetically altered, the most common genes when mutated 
increase the risk of developing breast cancer are: breast cancer susceptibility gene 1 
(BRCA1), breast cancer susceptibility gene 2 (BRCA2), P53, PTEN, CHEK2, ATM, and 
STKII. In addition to these genes SNPs in TGF-B1, CASP8 and PGR associated strongly 
with breast cancer risk (Shukla et al., 2014). 
The two major genes associated with tumor susceptibility in breast are BRCA1 and BRCA2 
as shown in Figure 4 (Wooster and Webber., 2003). Many genetic and epigenetic changes 
are involved in breast cancer development and progression such as somatic gene 
mutations, copy number aberrations, and miRNA expression (Byler et al., 2014). 
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Figure 4:  The Genetics of Breast Cancer (Wooster and Webber, 2003). 
 
1.1.10.1 Loss of Tumor Suppressor Genes: 
The most common tumor suppressor genes which are associated with Breast cancer include 
P53, BRCA1, BRCA2 and CHEK2 genes. 
High life time risk is associated with mutations in the high penetrance genes like p53, 
BRCA1, BRCA2 and CHEK2 genes: 
 P53 is a tumor suppressor gene that is produced in response to DNA damage, resulting 
in cell cycle arrest until damage is repaired or apoptosis takes place. It is considered the 
"Guardian of the cell", mutations in this gene decreases its activity, missense mutations 
in TP53 are more frequent in high-grade spontaneous breast carcinomas  suggesting 
that early p53 mutations might be one of the critical and decisive events in the 
development of breast cancer (Walerych et al., 2012). 
 BRCA1 and BRCA2 are tumor suppressor genes located on chromosome 17 and 13 
respectively. They are important for ensuring the stability of the genetic materials in 
the cells because they produce tumor suppressor proteins to help repair damaged DNA. 
Mutations or alterations in BRCA1 and BRCA2 increase the risk of Breast and Ovarian 
cancer (Larsen et al., 2014). Breast cancer risk estimates ranging from 59%-87% for 
BRCA1, and 38%-80% for BRCA2 mutations (Betty A.Mincey, 2003) 
 The CHEK2 gene provides instructions for making a protein called checkpoint kinase 2 
(CHK2). This protein acts as a tumor suppressor so it regulates cell division by 
preventing cells from keeping growing and dividing in an uncontrolled way. The 
CHK2 protein is activated in response to DNA damage; it interacts with several other 
proteins, including tumor protein TP53 to stop cell division and determine whether a 
cell will repair the damage or enter apoptosis (Desrichard et al., 2011). Mutations in 
the CHEK2 gene have been identified in some cases of breast cancer. A well 
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characterized mutation is a deletion of a single nucleotide at position 1100 in 
the CHEK2 gene (known as 1100delC). The 1100delC mutation is a breast cancer 
predisposition allele that leads to the production of an abnormally short, nonfunctional 
version of the CHK2 protein. So the cells can divide without control leading to develop 
cancerous tumors (Nevanlinna
 
and Bartek, 2006; Desrichard et al., 2011). 
 
1.1.10.2. Expression of Oncogenes: 
Activation of oncogenes contribute to the development of cancer, the most common 
oncogenes that have been associated with breast cancer are HER2, c-myc and Cyclines: 
HER2 oncogene:  Human epithelial receptor 2 gene is located on chromosome 17 and 
encodes a transmembrane tyrosine kinase growth factor. HER2 overexpression has been 
shown to play an important role in the development and progression of certain aggressive 
types of breast cancer like invasive breast cancer.  It is present in approximately 20–30% 
of breast cancer tumors. HER2 overexpression is associated with a more aggressive 
disease, higher recurrence rate, and shortened survival (Mitri et al., 2012) 
c-MYC oncogene: A regulator gene that codes for a transcription factor. It is involved in 
cellular proliferation and apoptosis. Amplification and overexpression of MYC oncogenes 
are associated with breast cancer in about 15%-25% of breast cancer (Osborne et al., 
2004). 
Cyclines and cell cycle modulators: Cyclines are regulators of cell cycle and proliferation 
process. Cyclin D1 and cyclin E play an important role in the progression of the cell from 
G1 to S phase, cyclin D1 is overexpressed in 40%-50% of invasive breast cancer (Osborne 
et al., 2004). 
 
1.1.10.3 Chromosomal Aberrations 
Chromosomal aberrations are one of the genetic abnormalities which have a role in the 
development of breast cancer. These aberrations contain known oncogenes and tumor 
suppressor genes (Kytola et al., 2000). For example, the amplification of MYC and 
CCND1 (which encode cyclinD1) plays a key role in developing drug resistance. 
There are many well established chromosomal abnormalities described in literature  such 
as numerous gains and losses, including: 
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 Recurrent DNA amplifications of many oncogenes; at 8p12 (FGFR1), 8q24 (MYC), 
11q13 (CCND1), 12q13 (MDM2), and 17q12 (HER2) (Kwei et al., 2010; Korkola and 
Gray, 2010). 
 Loss of specific regions of the chromosomes, such as deletion which has an important 
role in inactivation of tumor suppressor genes like PTEN, BRCA1 (17q21) deletion, 
BRCA2, and p53 (Albertson et al., 2003).Another common copy number deletion 
polymorphism in the APOBEC3 gene cluster located on chromosome 22 that has been 
associated with an elevated risk of breast cancer (Nik-Zainal et al., 2014). 
 The most common cytogenetic aberrations in breast cancer involve chromosome arms 
1q, 3p, and 6q, and translocation in chromosomes 8, 1, 17, 16 and 20 (Kytola et al., 
2000).  
Aberration in chromosome 8 is very common in many solid tumors including loss of 8p 
and gain of 8q, and involved in various translocations with other chromosomes. These 
alterations reflect the importance of chromosome 8 in the pathogenesis of breast cancer 
because it contains important oncogenes like c-MYC (Rummukainen et al., 2001). 
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1.2 Activation induced cytidine deaminase (AID) 
Activation induced cytidine deaminase AID is a member of APOBEC family of cytidine 
deaminase which deaminate cytidine in DNA leading to uridine (Figure 5-b). APOBEC is 
the Apolipoprotein B mRNA editing enzyme catalytic polypeptide-like (Takai et al., 2011; 
Michel Cogne., 2013). In humans, APOBEC family includes 11 members: APOBEC1, 
APOBEC2, series of seven APOBEC3 genes (A-C, DE, and F-H) , APOBEC4 and AID as 
shown in Figure (6) (Goila-Gaur and Strebel, 2008; Metzner et al., 2012). 
 
Figure 5: Activated Induced Cystisine Deaminase. (a) The primary structure of Activation 
induced cystidine deaminase AID. (b) Mechanism of cystidine deamination by AID enzyme 
(Chaudhuri and Alt, 2004). 
 
APOBEC family proteins contain characteristic domain structure, the catalytic domain on 
the N- terminal and the pseudocatalytic domain on the C-terminal. The proteins share 
conserved zinc-binding motif so the catalytic domain is a zinc dependent cytidine 
deaminase domain that is essential for cytidine deamination (Huthoff and Malim, 2005; 
Chiu and Greene, 2008 ; Goila-Gaur and Strebel, 2008) 
 
AID 
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Figure 6: Human APOBEC proteins. Members of the APOBEC family contain either one or two 
CDA domains. Proteins are aligned based on their (CDA) shaded in green. Catalytically inactive 
domains are shaded in red. The consensus sequence for the CDA domains is shown at the bottom. 
Chromosomal association is shown on the left (Goila-Gaur and Strebel, 2008). 
AID has been identified since 1999 by Honjo and colleagues, and initially thought to be an 
RNA-editing enzyme. It is encoded by Acida gene located on chromosome 12 (Seok-Rae 
Park, 2012). 
 
AID is a mutator enzyme that mutates DNA and RNA. It is an essential enzyme in B cells 
differentiation process, antibody maturation and diversification in vertebrate adaptive 
immune system (Mechtcheriakova et al., 2012). 
 
Recently, the structure of AID protein has been demonstrated (Figure 7). All AID models 
contain a core structure including a central beta sheet with four or five beta strands 
surrounded by six alpha helices with Zn-coordinating residues (King et al., 2015). 
 
 
Figure 7:  Three Dimensional Model of AID Protein. (A) Representative ribbon model of AID.  
N to C terminus progression is shown in color blue to red, with catalytic pocket zinc shown in 
purple. )B) Model of General surface topology of AID (King et al., 2015). 
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1.2.1 The Physiological role of AID 
Our immune system has defense mechanisms against a wide range of foreign antigens and 
pathogens with a broad diversity. DNA cytosine deamination by AID enzyme is a natural 
physiological event in the adaptive immune system (Pettersen et al., 2014). AID was 
initially thought to be an RNA-editing enzyme, but the discovery that it could 
mutate Escherichia coli DNA provided insight into its role as a DNA mutator enzyme 
(Conticello, 2008; Chandra et al., 2015). 
AID is expressed only in activated B cells under physiologic conditions. It is the key 
regulator of secondary antibody diversification mediating two main processes. The first 
process is Class Switch Recombination (CSR). In this process AID initiates the 
introduction of double strand DNA breakage in the heavy chain of the immunoglobulin 
leading to change it from one class to another, such as from the isotype IgM to the 
isotype IgG for antibody diversification (Franchini et al., 2013 ; Moris et al., 2014). 
The second process is Somatic Hypermutation (SHM) which allows the immune system to 
adapt its response to any threats during the lifetime of an organism. Somatic hypermutation 
involves a point mutation at the variable regions of immunoglobulin genes 
(Mechtcheriakova et al., 2012; Franchini et al., 2013; Moris et al., 2014). 
AID deficiency is responsible for the development of a rare immunodeficiency syndrome 
known as "Hyper-IgM Syndrome". The syndrome is characterized by increased levels of 
antibody IgM with absence of IgG, IgA and IgE resulting in high susceptibility to foreign 
pathogens and bacterial infections (Revy et al., 2000; Mechtcheriakova et al., 2012; Moris 
et al., 2014). 
Although AID expression in germinal center B cells which undergo CSR and SHM is at 
high levels, it is also found in other cell types such as oocytes, embryonic stem (ES) cells, 
and in estrogen-induced breast tissue. Its function in these cells remains to be elucidated. 
However, AID function is not limited to antibodies diversification, and evidence is 
accumulating to suggest a role in epigenetic reprogramming. AID knockout mouse 
model revealed that AID has a role in DNA demethylation during germ cell 
reprogramming (Moris et al., 2014). AID, along with the related cytidine deaminase 
APOBEC1, can convert 5-methyl C in single stranded DNA to thymidine in vitro. This 
observation led to the proposal that these enzymes could be the elusive vertebrate DNA 
cytosine demethylase. AID could initiate demethylation by a damage and repair 
mechanism similar to that used in SHM (Fritz and Papavasiliou, 2010). 
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1.2.2 The Role of AID in Cancer 
Genetic changes such as nucleotide alterations and chromosomal translocation in 
oncogenes and tumor suppressor genes, have an essential role in cancer formation and 
development (Takai, 2011). Most of the lymphomas diagnosed in the world arise from 
mature B cells and are characterized by the presence of chromosome translocations that 
involve one of the Ig loci and a proto-oncogenes (Yebenes, 2008). 
AID may function as a genome-wide mutator by mutating multiple genes. Studies show 
evidence that AID acts as DNA mutator in Escherichia coli this provided insights into its 
mechanism of action, thus,  if AID is expressed outside the immune system it can induce 
cancer in various tissues (Paulkin, 2009). Aberrant expression of AID cause genomic 
instability and mutating multiple genes by favoring chromosome translocations and point 
mutations in both B and non-B cells, thereby stimulating cancer formation. Thus AID 
could have a strong contribution to human malignancy, including solid tumors.  AID 
expression has been reported in numerous cancers of non-B-cell origin, including breast, 
prostate, stomach, liver, and lung (Park, 2012; Mechtcheriakova et al., 2012 ; Moris et al., 
2014 ; Petterson et al., 2014). 
Recent sequencing of large numbers of human cancer genomes showed that mutations at 
cytosine residues, particularly C to T transitions, are the most prevalent mutations in 
human cancer, highlighting the enzyme AID as a potential source of mutagenesis. Other 
factors, including expression levels for uracil-DNA glycosylase may modulate genomic 
uracil levels and can be also introduced by coupling with replication of U/G mismatches 
but aberrant AID levels have the strongest effect leading to genes mutagenesis (Kotani et 
al., 2005; Petterson et al., 2014). 
In mice, AID expression was necessary for translocations between Ig loci and proto-
oncogenes, a hallmark of several human B-cell lymphomas. For example deregulated 
expression of AID has been proved to trigger c-myc/Igh translocations (a common trait in 
Burkitt's lymphoma) and c-myc/miR-142 found in B cell leukemia (Conticello, 2008; 
Moris et al.,2014). In contrast, AID knockout mice have fewer translocations and fewer 
mutations in genes linked to B cell tumorigenesis (Petterson et al., 2014). 
Constitutive or ubiquitous AID expression also leads to cancer development that is 
characterized by point mutations in oncogenes like PIM1, MYC, p53, Bcl-6, RhoH/TTF 
(ARHH), and PAX5 (Chiu., 2009 ; Takai., 2011 ; Mechtcheriakova et al 2012 ; Moris et al., 
2014). It has recently been reported that aberrant expression of AID in gastric epithelium 
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leads to the accumulation of nucleotide alterations in the p53 gene. So AID Aberrant 
expression in human cells increases the mutation rate of p53 by around 10 folds (Borchert, 
2011). 
This associations between AID with cancer has been well established and it is an indication 
on how tight intracellular regulation of AID enzyme is needed to minimize the chances of 
alterations in genomic DNA leading to cellular transformation (Conticello, 2008; Chiu, 
2009). 
1.2.3 Regulation of AID Expression 
The identification of AID as a potential mutation inducer indicates the importance of its 
regulation to avoid dramatic side effects and genomic instability. AID is under the control 
of transcriptional, post-transcriptional and post-translational levels of regulation 
(Aoufouchi et al., 2008; Borchert et al., 2011; Cogne, 2013; Rebhandl et al., 2015).  
Transcription factors including Pax5, HoxC4 and NF-KB control the AID promoter to 
yield high levels of AID expression in the B cell lineage. HoxC4-binding site located in the 
promoter region upregulates AID transcription. In addition to these enhancers, E2F- and c-
Myb binding sites in region 2 of the AID promoter function as silencers that negatively 
regulate AID promoter activation.  NF-κB and STAT6 are major transcription factors in 
the CD40, IL-4, and TGF-β signaling pathways mediated by toll-like receptors and 
cytokines, which are associated with inflammatory reactions, therefore activation of NFkB 
is important for its ability to induce AID expression (Dedeoglu et al., 2003; Huong Le et 
al., 2013; Chandra et al., 2015). Mutations in CD40 gene cause hyper IgM (HIGM) 
syndrome which is characterized of very low levels of serum IgG, IgA and IgE as a 
consequence to the loss of CSR process that results from AID activation (Xu et al., 2007; 
Frasca et al., 2008). 
Microbes and pathogens induce AID expression by activating intracellular transduction 
pathways such as CD154 and IL-4 ( Xu et al., 2007; Cogne, 2013). AID expression is 
induced in gastric epithelial cells by Helicobacter pylori (H. pylori) infection through the 
NF-κB pathways suggesting that inflammatory signals associated with infection by 
pathogens are involved in inducing AID (Huong et al., 2013). 
Chronic inflammation pathophysiology associated with the transcriptional factor NF-κB 
which is activated by various proinflammatory cytokines. NF-κB plays a key role in the 
upregulation of AID expression, and many studies suggest that activation of NF-κB  in 
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epithelial cells under many inflammatory conditions might induce AID, leading to genetic 
instability (Figure 8) (Shimizu et al., 2012). 
 
 
 
Figure 8: Activation-induced cytidine deaminase (AID) function under physiological 
and inflammatory conditions. (Left picture) Under physiological conditions, AID is 
expressed only in activated B cells and is a key molecule for generating immune diversity by 
inducing (SHM) and (CSR) in immunoglobulin genes. (Right picture) Under inflammatory 
conditions, AID is aberrantly expressed in epithelial cells. AID can induce somatic mutations and 
chromosomal aberrations in tumor-related genes, contributing to malignant transformation 
(Shimizu et al., 2012). 
AID transgenic mice develop gastric neoplasms suggest that aberrant AID expression in 
gastric epithelial cells contributes to cancer development by the accumulation of somatic 
mutations. AID is induced in response to H. pylori infection or proinflammatory cytokine 
like TNF-alpha stimulation via the NF-B signaling pathway and is capable of contributing 
to the generation of somatic mutations in various tumor-related genes such as TP53. Thus, 
inflammation-mediated AID expression plays a key role in genetic instability and cancer 
developing (Figure 9) (Marusawa, 2008).  
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Figure 9: AID links chronic inflammation to gastric cancer development by its mutagenic 
activity (Marusawa, 2008). 
 
AID is post-transcriptionally regulated by several mechanisms including microRNA 
regulation, phosphorylation, nucleo-cytoplasmic shuttling and ubiqitination, all of which 
play important roles in regulating AID and function in SHM and CSR ( Xu et al., 2007 ; 
Basu et al., 2009). Phosphorylation of AID is necessary for its activation, protein kinasa A 
(PKA) phosphorylates messenger of AID on Serine38 in cells including activated B cells. 
Recent studies show that drug-induced PKA inhibition decrease CSR while PKA 
activation-by deletion of PKA negative regulatory subunit-increase CSR through AID 
activation (Basu et al., 2009; Cogne et al., 2013; Yi Hu et al., 2014). 
As DNA deaminase, AID would perform its function in the nucleus, after that it must be 
retained to the cytoplasm. Nuclear localization signal (NLS) at the amino terminus of 
human AID regulates the dynamic shuttling of AID between the cytoplasm and the 
nucleus. Subcellular localization is an important step in regulating AID that affect its 
stability because AID has a significantly shorter half-life in the nucleus than in the 
cytoplasm (Xu et al., 2007; Orthwein et al., 2010; Cogne, 2013; Yi Hu et al., 2014). 
The correlation between the endocrine system and the immune system is well documented. 
Estrogen has stimulatory effect immune response. Studies show that AID can be activated 
by estrogen in immune and non-immune cells. This provides an evidence of how estrogen 
can alter the immune system and induce oncogenic DNA alterations (Pauklin et al., 2009). 
Estrogen mediating genome instability via the activation of AID may provide a novel 
molecular mechanism that is important for breast cancer pathology (Pauklin et al., 2009; 
Mechtcheriakova et al., 2012).  
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Estrogen directly and indirectly activates AID expression; this can lead to immune hyper-
stimulation. Estrogen receptor (ER) binds the AID promoter directly, or indirect via 
activation of transcription factors that enhance AID expression (Incorvaia et al., 2013). 
Therefore estrogen is able to induce a DNA mutator in a variety of hormonally responsive 
cells (Figure 10). These findings might explain why women are more susceptible to 
autoimmune diseases and cancer in particular breast cancer (Orthwein and Noia, 2012). 
These studies brought the light to this research since 70% of BC are estrogen receptor 
positive, estrogen can mediate genome instability via the activation of AID and other DNA 
deaminases (Persyamy et al., 2015).  
 
 
 
Figure 10: Model of AID activation by Estrogen leading to DNA damage. Extracellular 
estrogen enters the cell, binds to the estrogen receptor dimer (ER), is transported as a 
ligand complex into the nucleus, binds near the AID promoter, and activates AID 
transcription (Petersen-Mahrt et al., 2009). 
 
Recent evidence suggests that one level of AID regulation comes from microRNA      
(miRs). These short noncoding RNA regulates many genes by repressing translation or 
directing mRNA destruction through partial sequence complementarity to 3 untranslated 
regions (3UTR) of target mRNA. MiR-155 repress AID and the disruption of the miR-155 
increase AID-induced c-MYC translocation, this may explain why disruption of miR-155 is 
associated with Burkett's lymphoma. It is characterized by AID-induced mutation and a 
translocation between c-MYC proto-oncogene and the IgH loci (Dorsett et al., 2008; 
Borchert et al., 2011). 
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1.3 Objectives: 
Recently, researches have shown the aberrant AID expression in different types of cancer. 
This causes genomic instability thereby stimulating cancer formation. In Palestine one 
study was reported in 2013 showed that AID may be involved in a subset of lung cancer 
and since then no studies are reported (Data unpublished). 
The aim of this study is to evaluate for the expression of AID protein in breast cancer taken 
from patients in Palestine and to determine the correlation between AID protein expression 
and clinico-pathological data of the patients, such as age, BC type, BC grade, BC stage and 
invasiveness. This is the first study that examines the expression of AID protein in BC 
tissue samples by IHC in Palestine and worldwide.  
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Chapter Two: Materials and Method 
 
2.1. Materials 
Reagents and buffers used in IHC and H&E staining are listed in table 2 below. 
Table 2: Materials for IHC and H&E staining 
   
Material   
 
Company Catalog# 
Xylene 
 
Loba Chemie Cas#: 1330-20-7 
Ethanol 
 
Carlo Ebra 64-17-5 
Citrate buffer pH=6 
 
Invitrogen Ref#: 005000 
Hydrogen peroxide 3% 
 
MP Biomedicals, USA Article#: 194057 
Pap –pen 
 
Invitrogen  00-8899 
TBS buffer 
 
Sigma T5912-1L 
Primary AID Ab 
 
e-Bioscience 14-5959 
Cass block 
 
Invitrogen 0-8120 
Secondary anti-Rat  Ab 
 
Histofine 414311F 
DAB chromagen 
 
Cell-Marque 957D-31 
DAB buffer substrate 
 
Cell-Marque 957D-32 
Hematoxylene 
` 
Sigma GHS3128-4L 
Mounting Medium 
 
Fluka 03989-10ML 
Super Frosted Plus Slides 
 
Fisher brand 12-550-15 
Eosin Y       Sigma E6003-25G 
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2.2. Methods 
 
2.2.1 Sample collection: 
Archived paraffin embedded blocks of 69 breast cancer samples were collected 
retrospectively from the Pathology Department at Beit Jala Hospital in Bethlehem city 
between years (2009 - 2013). Breast cancer cases were accompanied with their 
pathological reports obtained from the hospital records archive. The pathological reports 
contain data about the patients including: Age, gender, data of specimen collection, tumor 
grade and stage. The study design was approved by the Faculty of Medicine at Al-Quds 
University and Beit Jala Hospital. 
 
2.2.2. Tissue Sectioning: 
For light microscopy, the microtome is used to cut three micrometer-thick tissue sections, 
since it is the ideal thickness for IHC. The tissue sections are mounted on a super frosted 
plus glass microscope slides.  These slides provide maximum adhesive protection and thus 
the tissues won't fall off the slides. The slides are charged to create a strong bond between 
fresh, frozen or formalin fixed paraffin embedded tissue sections and glass slides. Each 
case block was cut into two sections; one section was prepared for H&E staining for 
histological diagnosis and evaluation, and the other section for IHC staining. 
 
2.2.3. Standard Staining (H&E): 
Standard stain Hematoxylene and Eosin was performed for each breast cancer case for 
histological diagnosis and evaluation by the pathologist, and as reference for each IHC 
stained slide to see the original tissue, and to confirm the tumor stage and grade when there 
is missing data in the patients reports. The protocol was done as shown below in table 3 
(Avwioro, 2011). 
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Table 3: H&E Staining Protocol 
Treatment 
 
Time 
Xylene 1 
 
2 min 
Xylene 2 
 
2 min 
Ethanol 100% 
 
1 min 
Ethanol 80% 
 
1x5sec 
Ethanol 70% 
 
1x5sec 
Tap water 
 
3 min 
Hematoxylene 
 
2-4 min 
Tap water 
 
Wash 
Eosin 
 
5-6 min 
Tap water 
 
3 min 
Ethanol 70% 
 
1x5sec 
Ethanol 80% 
 
1x5sec 
Ethanol 100% 
 
I min 
Xylene 1 
 
2 min 
Xylene 2 
 
2 min 
Mounting solution and cover glass  
 
2.2.4. Immunohistochemistry (IHC) 
Immunohistochemistry has become a crucial technique and widely used in medical 
research and diagnosis. IHC currently has many clinical applications in diagnosis, 
prognosis, therapeutic decision making, and pathogenesis. The principle of IHC bridges 
three disciplines: Immunology, histology, and chemistry. The fundamental concept of this 
technique is the demonstration of antigens within tissue sections by means of specific 
antibodies.  Antigen-antibody binding is demonstrated with a colored histochemical 
reaction that is visualized by number of ways. In the most common an antibody is 
conjugated to an enzyme, such as peroxidase that can catalyze a color-producing reaction 
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or the antibody can be tagged to a radioactive element, and can be visible using light or 
fluorescent microscopy. In contrast to many detection techniques, IHC allows localization 
of an antigen in tissue sections thereby dramatically enhancing diagnostic interpretation 
and understanding of the pathogenesis (Ramos-Vara and Miller, 2014; Rizzardi et al., 
2012) 
All tissue sections mounted on superfrosted slides were treated according to the protocol of 
immunohistochemistry as in table 4 (Ramos-Vara, 2005). 
 
IHC staining controls are required for validation of staining results to ensure that every 
IHC test is performed correctly and the immunostains are working. Positive tissue control 
is tissue with the specific antigen that is known to show positive reaction with the 
antibody, the purpose of using positive control is to ensure correct staining. Negative tissue 
control is tissue without the specific antigen present, and the purpose is to document 
specificity of the staining (Chan et al., 2000; Packeisen et al., 2002). 
In this project the positive control used for AID antibody was sections from tonsil tissue 
since tonsils are the first line of defense against pathogens they express high levels of 
cytoplasmic AID. These control slides are kindly provided from Beit Jala Hospital. 
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Table 4: Immunohistochemistry protocol. 
Treatment Time Notes 
Xylene 1 20 min Deparafinization 
                     Xylene 2                                                                                 10 min Deparafinization 
             Ethanol 100% 3x3 min To remove dissolved paraffin 
wax and xylene 
Ethanol 96% 3min Rehydration 
Ethanol 80% 3min Rehydration 
DDW 3x5sec Washing to rinse off Ethanol 
Citrate buffer (pH6) 20 min, medium power , 
in microwave 
To enhance Antigen exposure 
DDW 3x2 min Washing 
3% Hydrogen peroxidase 10 min Block endogenous Peroxidase  
DDW 3x1 min Washing 
Surround circle the tissue  By using Pap pen 
TBS buffer 3x2min Washing  
Primary AID antibody Overnight Incubated at 4C, diluted 1:50,  
TBS buffer 3x5min Washing 
Secondary Anti Rat-Ab 30 min 2 drops (0.1 ml) 
TBS buffer 3x5min Washing 
DAB chromagen 20 min "substrate chromagen" 
DDW 5sec Washing 
Hematoxylene 30 sec Counter stain 
Tap water 5 sec Washing 
Ethanol 96% 2 min Dehydration 
Ethanol 100%                              2 min  Dehydration 
Xylene 1 2min  
Xylene2 2min  
Mounting solution and cover glass   
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At the beginning of the IHC protocol slides must be deparrafinized and rehydrated since 
incomplete paraffin removal can cause poor staining of the section, therefore xylene and 
graduated concentration of alcohol were used. 
When using a new antibody in IHC protocol, the antibody must be calibrated to find the 
optimal staining conditions. Each antigen has a preferred method of antigen retrieval and 
each antibody has an optimal dilution. 
Fixation process of the slides lead to conformational changes such as the formation of 
methylene cross-links which masks the antigens and cause very poor staining by IHC. 
Antigen retrieval by heat is necessary to the hydrolysis of methylene bridges and unmasks 
the antigens in order to allow the antibodies to bind, so as to get good and efficient stain 
for the antigen. The two methods of antigen retrieval are heat mediated (also known as 
heat-induced epitope retrieval (HIER) and the enzymatic method (Paulsen et al., 2015). 
 For performing heat induced antigen retrieval proper buffer should be used (e.g., citrate, 
Tris) with  various pH (3–10), but for most antigens citrate buffer (pH 6.0) will give 
satisfactory results and good cell morphology when compared with buffers with higher pH 
or solutions containing EDTA (Ramos-vara, 2005). 
Heat mediated antigen retrieval can be done using a pressure cook, microwave or hotplate. 
In this research the microwave was used. AID antigen was calibrated by using different 
levels of powers at different timing; at High power 350-375 degrees for (15, 20 min) and at 
Medium power 300-350 degrees for (15, 20 min), the best results were obtained at Med 
power for 20 minute with Citrate buffer (pH 6). 
The sensitivity of an immune reaction mostly depends on the detection system used. The 
Ag-Ab reaction cannot be seen with the light microscope unless it is labeled. Therefore, 
reporter molecules are attached to the Abs to allow visualization of the immune reaction. 
There are a variety of labels used, including fluorescent compounds, enzymes, and metals. 
The most commonly used labels are enzymes (e.g., peroxidase, alkaline phosphatase, 
glucose oxidase). Enzymes in presence of a specific substrate and a chromagen will 
produce a colored precipitate at the site of the Ag-Ab binding (Ramos-vara, 2005). 
Detection systems are classified to direct and indirect methods. Direct methods are one-
step process with a primary Ab conjugated with a reporter molecule. The method lacks 
sufficient sensitivity for the detection of most antigens. The need for more sensitive Ag 
detection develop a two-step method, the indirect method in which the first layer of Abs is 
unlabeled and called the primary antibody, but the second layer, raised against the primary 
Ab, is labeled and called the secondary antibody. The sensitivity of this method is higher 
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because it is resulting in a strong signal and the number of labels per molecule of primary 
Ab is higher, increasing the intensity of reaction (Ramos vara, 2005). 
 
In this research indirect detection system was done, the primary antibody is monoclonal 
Anti-Human/Mouse Activation Induced Cystidine Deaminase (the concentration is 0.5 
mg/ml), it recognizes human and mouse AID. Calibration for the accurate dilution of the 
AID antibody was done in a previous study on the same AID protein done for lung cancer 
tissue sections, and the optimal staining result was obtained by the dilution 1:50 Ab into 
Cass block. Cass block is a universal blocking agent for reducing nonspecific background 
staining in immunolabeling techniques, and works well as a diluting reagent for primary 
antibodies. Calibration for the accurate slides incubation of the primary AID Ab was done 
(One hour incubation at room temperature and overnight incubation at 4
0 
C) and the perfect 
results were obtained at overnight incubation for primary AID Ab. The amount of Ab for 
each slide was 2.6 microliter.  
Unwanted background staining due to endogenous enzyme activities is no longer a 
problem in immunohistochemistry (Buchwalow et al., 2011). That’s why we treat the 
slides with 3% Hydrogen Peroxide (H2O2) to block the endogenous peroxidase activity 
which may lead to false positive results, since we are using 3', 3’ Diaminobenzidine DAB 
as a substrate for peroxidase enzyme labeled on the secondary Ab. 
The secondary Ab used in this experiment is labeled with horse radish peroxidase (HRP), 
so we used DAB substrate chromagen for detection system (2.6 microliter for each slide), 
it enables the antibody- antigen complex to be viewed easily under the light microscope. It 
is oxidized by peroxidase (HRP) and gives dark brown color. Slides were incubated with 
DAB at different timing; 15 min, 20 min, 30 min, and the best results were obtained at 20 
min.  
Evaluation of AID protein expression in the BC treated slides was done by the pathologist 
in Beit Jala Hospital Dr. Riyad Shrem. The intensity of cytoplasmic expression classified 
according to the three grade scale (0: no staining, 1+: focal positive staining, 2+ moderate 
positive staining and 3+ very strong positive staining) (Rizzardi et al., 2012). 
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2.2.5. Statistical Analysis: 
Statistical analysis was done to find if there is a significant correlation between AID 
protein expression in Breast Cancer tissues with the clinico-pathological data of BC cases. 
Pearson's chi-squared test was used, and converted to P-value. If the P-value <0.05 it was 
considered to be statistically significant, the statistical program SPSS was used. 
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Chapter Three: Results 
 
3.1. Study Samples: 
The general clinical and pathological data of Breast Cancer cases are summarized in Table 
5; including age, BC type, BC stage and Tumor Grade. 
IHC was performed on 69 BC cases and on control slides from tonsil tissue. 
For further confirmation 10 slides were chosen randomly and IHC was repeated and 
showed similar results.  
 
Table 5: Clinico-pathological Data and AID Expression for the BC Cases. 
Slide 
# 
 
Block # Age BC Type BC Stage Tumor Grade AID 
Exp. 
1 1655-12 68 IDC T4NxMx G3 Poorly d. 0 
2 1945-12 48 IDC T2N2Mx Moderately d. +1 
3 186-10 40 IDC T1N2Mx G2 Moderately d. 0 
4 2557-12 57 IDC T2N3Mx G2 Moderately d. +1 
5 2347-12 37 IAC T2NoMx G3 Poorly d. 0 
6 2637-12 38 IDC T2N3Mx G2 Moderately d. +2 
7 2818-12 57 IDC t2N3Mx G2 Moderately d. 0 
8 2817-12 41 IDC T3N2Mx G2 Moderately d +1 
9 1019-12 64 IDC T2N0Mx G2 Moderately d +1 
10 1286 56 IDC T3N2Mx G2 Moderately d. +1 
11 3545-12 53 IDC T2N1Mx G2 Moderately d. 0 
12 219-09 44 IDC TxN2Mx Moderately d +1 
13 640-09 72 IDC TxN1Mx G2 Moderately d. 0 
14 556-12 43 IDC T1N1Mx G2 Moderately d. 0 
15 1114-12 29 IDC T4N2Mx G2 Moderately d. 0 
16 2649-12 45 IDC T2N0Mx G2 Moderately d. 0 
17 3299-12 29 IDC - - 0 
18 402-11 71 IDC T2N0Mx G2 Moderately d. 0 
19 646-11 77 IDC T2N0Mx G2 Moderately d. 0 
21 1226-11 32 IDC TxN3Mx Moderately d. 0 
22 1527-11 49 IDC T2N2Mx G2 Moderately d. 0 
23 1618-11 55 IDC T2N0Mx G2 Moderately d. 0 
24 1631-11 43 IDC TxN3Mx G2 Moderately d. 0 
25 2174-11 64 IDC T2N0Mx G2 Moderately d. 0 
26 2756-11 41 IDC T3N2Mx G3 Poorly d. 0 
27 2977-11 54 IDC - - 0 
28 3007-11 60 IDC T1N0Mx G2 Moderately d. 0 
29 3369-11 47 IDC T3N3Mx G3 Poorly d. 0 
30 3488-12 42 IDC G2 Moderately d. 0 
31 
 
31 183-09 40 IDC TxN3Mx Moderately d. 0 
32 1308-09 86 IDC - - 0 
33 3147 45 IDC - - 0 
34 1887-09 75 IDC TxN2Mx Moderately d +1 
35 2195-09 46 IDC - - 0 
36 2145-09 39 IDC TxN0Mx Moderately d. 0 
37 2224-09 54 IDC T2N1Mx Moderately d. +1 
38 2353-09 49 IDC T4N0MX G2 Moderately d. 0 
39 2686-09 59 IDC - - 0 
40 2712-09 69 IDC TxN1Mx Moderately d. 0 
41 2783-09 52 IDC T2N0Mx G2 Moderately d. +1 
42 2843-09 71 IDC T2N0Mx Moderately d. 0 
43 2859-09 34 IDC G2 Moderately d. 0 
44 1655-12 68 IDC T4NxMx G3 Poorly d. 0 
45 2995-09 43 IDC TxN2Mx Moderately d. +1 
46 3830-09 34 IDC T0NxMx Moderately d. 0 
47 3402-09 52 IDC T1N1Mx Moderately d. 0 
48 3387-09 54 IDC T1N1Mx Moderately d. 0 
49 3313-09 45 IDC T2N3Mx G2 Moderately d. +1 
50 502-10 33 IDC T3N3Mx Moderately d. +1 
51 978-10 49 IDC T2N1Mx G3 Poorly d. +2 
52 1410-10 50 IDC T2N2Mx G2 Moderately d. 0 
53 185-10 53 IDC T4N2Mx G2 Moderately d. 0 
54 1988-10 47 IDC T2N1Mx G2 Moderately d. +1 
55 1671-10 61 IDC T2N2Mx G2 Moderately d. +1 
56 2689-10 42 IDC T1N1Mx G2 Moderately d. 0 
57 780-10 31 IDC T2NxMx G2 Moderately d. 0 
58 2048-10 46 IDC T2N2Mx G2 Moderately d. 0 
59 1728-10 58 IDC - - 0 
60 1183-10 63 IDC T4N3Mx G3 Poorly d. 0 
61 2616-10 46 IDC T3NxMx G2 Moderately d. 0 
62 514-10 77 IDC - - 0 
63 1618-10 49 IDC T3N3Mx G2 Moderately d. 0 
64 2546-10 34 IDC T4N3Mx G2 Moderately d. 0 
65 774-10 46 IDC T2N3Mx G2 Moderately d. 0 
66 1164-10 35 IDC T4N3Mx G2 Moderately d. 0 
67 3540-10 38 IDC - - 0 
68 2967-10 55 IDC T3N1Mx G2 Moderately d. +1 
69 3576-10 46 IDC - - +1 
71 2487-10 36 IDC - - 0 
 IDC: Invasive Ductal Carcinoma 
 Gender not involved because all BC cases are for Females patients 
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3.2 Clinico-pathological data summary for BC cases: 
As seen in table 6; 100% of the patients were females. Ages of the patients range from 29 
and 86 years, with an average of 49.5 years old. 
In this study 100% of the patients have Invasive Ductal Carcinoma also called Infiltrative 
Ductal Carcinoma. 
According to the national cancer institute there are three grades of BC: 
• Grade 1 (well differentiated  grade): Cancer  cells look similar to normal cells and 
grow very slowly. 
• Grade 2 (moderately differentiated grade): Cancer cells look more abnormal and 
faster growing. 
• Grade 3 (poorly differentiated grade): Cancer cells look very different from normal 
cells and grow quickly.  
Tumor Grade ranges between moderately differentiated 91%, and poorly differentiated 9%. 
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Table 6: Summary of Clinico-pathological Data of BC cases. 
 
Patient characteristics  Frequency (%) 
 
Gender 
 
Male 
Female 
 
0 (0%) 
69 (100%) 
 
 
 
 
Age 
 
Range 
 
≥60 
 
<60 
 
Average 
 
 
29-86 
 
14 (20.3%) 
 
55 (79.7%) 
 
49.5 
 
BC type: 
 
IDC 
Insitu DC 
 
69 (100%) 
0 (0%) 
 
Tumor Grade 
 
Poor d 
 
Mod d 
 
Well d 
 
4 (9 %) 
 
44 (91 %) 
 
0 
 
Tumor Stage 
 
 
 
 
 
 
 
Tumor Stage 
 
T0 
Tx  
TI 
T2 
T3 
T4 
 
 
N0 
Nx 
N1 
N2 
N3 
 
1 (2%) 
9 (16%) 
6 (11%) 
24 (43%) 
8 (14%) 
8 (14%) 
 
 
12 (21%) 
5 (9%) 
11 (19%) 
15 (26%) 
14 (25%) 
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3.3 IHC Evaluation and Statistical Analysis for the BC cases 
Positive controls which are tonsils tissue sections were stained in brown with cytoplasmic 
localization (Figure 11-a) At 10X magnification, and (Figure 11-b) at 100X magnification. 
Figure 11-a: Cytoplasmic AID Expression in Positive Control at 10x magnification. 
Figure 11-b: Cytoplasmic AID Expression in Positive Control at 100x Magnification 
  
                            a                                                                                   b 
AID protein expression was detected in 26% (18 of 69) of BC cases with cytoplasmic 
localization (Figure 12).  
  
Figure 12: Positive AID expression in BC tissues at 10x magnification (a), (c), (d),  at 
100x magnification (b). 
  
                       
                        a                                                                                         b                    
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                  c                                                                                            d 
Negative AID expression tissues was in 51 slides of 69, results were as shown in figure 13. 
Figure 13: Negative AID Expression in BC Tissues. 
  
                         a                                                                                                                   b 
 
                                                                   c 
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Table 7 below describes the correlation between AID protein expression and Clinico-
pathological parameters, 79.7% of the positive cases were more than or equal to 60 years, 
20.3% were below the age of 60 years. However, no significant difference  was obtained 
between the two groups of age and AID expression (p=0.747). Moreover, 68.6% and 12 % 
of moderately and poorly differentiated tumor showed AID protein positive, respectively. 
No significant difference was found between BC tumor grade and AID expression 
(p=0.081). On the other hand, all tumor stages showed AID protein positive; stage T2 was 
the dominant with a percentage of (36.2%), but no significant difference was observed 
between the tumor stage and AID expression (p=0.907). Since we are studying Breast 
cancer all the cases were females so p value can’t be found and also for the BC type since 
all the cases are the same BC type. Some cases did not have complete clinical data, and 
were not included in the table. 
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Table 7: Correlation between AID Protein and Clinico-pathological Parameters. 
 
 Variable/AID 
 
0 
 
+1 
 
+2 
 
Total 
 
% of Cases 
 
X
2
 
 
P value 
 
Gender 
 
M 
 
F 
 
 
 
0 
 
51 
 
 
 
0 
 
16 
 
 
 
0 
 
2 
 
 
 
0 
 
69 
 
 
 
0% 
 
26% 
 
Ø 
 
Ø 
 
Age 
 
<60 
 
≥60 
 
 
 
40 
 
11 
 
 
 
13 
 
3 
 
 
 
2 
 
0 
 
 
 
55 
 
14 
 
 
 
27% 
 
21% 
 
0.584 
 
 
 
0.747 
 
 
 
BC Type 
 
IDC 
 
INDC 
 
 
 
 
51 
 
0 
 
 
 
16 
 
0 
 
 
 
2 
 
0 
 
 
 
69 
 
0 
 
 
 
26% 
 
0% 
 
Ø 
 
Ø 
 
Tumor Grade 
 
Well d. 
Moderately d. 
Poorly d. 
 
 
 
 
0 
35 
6 
 
 
 
0 
15 
0 
 
 
 
0 
1 
1 
 
 
 
0 
51 
7 
 
 
 
0% 
31% 
14% 
 
5.025 
 
0.081 
 
Tumor Stage 
 
Tx 
T1 
T2 
T3 
T4 
 
Nx 
N1 
N2 
N3 
N0 
 
 
 
6 
7 
15 
5 
7 
 
5 
7 
7 
10 
10 
 
 
 
3 
0 
8 
3 
0 
 
0 
3 
7 
3 
2 
 
 
 
0 
0 
2 
0 
0 
 
0 
1 
0 
1 
0 
 
 
 
9 
7 
25 
8 
7 
 
5 
11 
14 
14 
12 
 
 
 
 
33% 
0% 
40% 
38% 
0% 
 
0% 
36% 
50% 
29% 
17% 
 
8.966 
 
0.907 
 X2: Chi square test. P-value≤ 0.05, AID protein expression versus Clinico-pathological 
parameters. 
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Hormone receptor status: 
Estrogen receptor (ER), progesterone receptor (PR) and  HER-2 receptors are found on 
breast cells. Overexpression of these receptors are called hormone-receptor positive in the 
pathology reports. Table 8 show the hormone receptor status for 29 cases of BC (Data 
available only for these cases).  Estrogen-estrogen receptor complexes directly bind to the 
AID promoter and enhance AID transcription, leading to AID expression induction. 
 
Table 8: Hormone receptor status. 
HER-2 
status 
PR status ER status AID 
Expression 
Case #  
+  - -+ 41 1- 
 -+  -+ 94 -2 
+ + + + 05 3- 
 -+ + + 05 4- 
 + + + 09 0- 
 - -+ + 00 6- 
 -+ +  -3 7- 
  - - -55 8- 
 - - - -59 9- 
 + +  -51 10- 
 -+ +  -51 11- 
 + +  -54 12- 
 -+  - -22 13- 
 - - - -21 14- 
 - - - -21 15- 
 -+ +  -24 16- 
 + +  -91 17- 
 + -  -94 18- 
 -+ +  -02 19- 
 + +  -03 20- 
 - - - -04 21- 
  - - -15 22- 
 + +  -12 23- 
 + +  -13 24- 
  - - -19 25- 
 -+  - -10 26- 
+ + +  -11 27- 
 +  - -14 28- 
 -+ +  -45 29- 
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Chapter Four:  
 
4.1 Discussion 
Activation induced cytidine deaminase (AID) is expressed  in germinal center B cells, it is 
essential in the affinity maturation of Immunoglobulin chains during B cell differentiation, 
through two processes: SHM and CSR which take place in secondary lymphoid tissues 
(lymph nodes, tonsils, and spleen) (Kalchschmidt et al., 2016; Pefanis and Basu, 2015). 
AID supports acquired immune system diversification thus humans lacking AID are 
severely immunocompromised (Khair et al., 2015). 
AID is a physiological tool to introduce DNA alterations and may function as a general 
genome-wide mutator enzyme. In addition to diversifying the immune repertoire, AID can 
also target non-Ig genes. It has been shown that abnormal AID expression in non-B cells 
contributes to human malignancy including solid tumors (Mechtcheriakova et al., 2012; 
Kanu et al., 2016). 
The mutagenic potential of AID makes its expression and activity tightly regulated on 
different levels to minimize the risk of unwanted DNA damage. However, chronic 
inflammation and other factors have been shown to trigger aberrant AID expression in B 
cells and, importantly, in non-B-cell background. Under these circumstances, AID may 
also target non-Ig genes. These include cancer-related genes such as oncogenes and tumor 
suppressor genes. AID expression leads to increased mutation rate of TP53, and genomic 
stability genes (Mechtcheriakova et al., 2012; Casellas et al., 2016).  
Aberrant expression of AID in somatic cells plays a critical role in carcinogenesis. 
Transgenic mice with overexpression of AID are exposed to tumorgenecity and had 
developed malignant T cell lymphomas and micro-adenomas in lung with frequent point 
mutations which appeared to be introduced by AID activity. Therefore, these studies 
suggested that deregulated AID could be responsible for human malignancy (Okazaki et 
al., 2003; Tatemishi et al., 2014). Several studies have reported that AID is aberrantly 
expressed in several cancer types such as hepatocellular carcinoma, lymphoma and 
leukemia (Park, 2012), pancreatic tumorigenesis (Sawai et al., 2015), gastric cancer, 
colorectal cancer (Nonaka et al., 2016), breast cancer (Harris, 2015; Rebhandl et al., 2015; 
Munoz et al., 2013; Babbage, 2006) and lung cancer (Shinmura et al., 2011). These 
observations suggest that aberrant AID expression causes mutations in various oncogenes 
or tumor-suppressor genes and these mutations induce tumor formation. 
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In this regards, immunohistochemistry (IHC) is widely used in cancer research including 
breast cancer, because it is an important complementary tool for the routine diagnosis of 
cancer and for the identification of the different histological types and prognostic factors. 
IHC is also used to categorize patients in order to ensure appropriate and specific treatment 
and therapy response (Capelozzi, 2009). 
 
In the present study, we examined the expression of AID protein in breast cancer tissue 
sections derived from Palestinian patients paraffin embedded blocks using IHC technique. 
AID immunostaining was localized mainly in the cytoplasm in accordance with previous 
studies (Shinmura et al., 2011; Marusawa., 2008; Endo et al., 2008; Babbage et al., 2006). 
Our results revealed that AID protein is overexpressed in 26.1% of BC cases (18 of 69). 
In consistent with a study reported by Babbage et al showed that AID protein is over 
expressed in 36.4% (35 of 96) of the cell lines examined (Babbage et al., 2006). Protein 
level of AID was not detected in normal breast tissue since AID protein is not expressed 
under physiological conditions in normal tissue other than tonsils and lymph nodes for 
antibody diversification through CSR and SHM mechanisms (Perez-Duran et al., 2007). 
Our results showed no significant correlation between AID protein expression and clinico-
pathological parameters; age, tumor stage and tumor grade. 
A Study by Babbage et al 2006 reported the expression of AID in three cell lines of breast 
cancer. The number of cells positive for AID was 35 out of 96, so the frequency of single 
cells expressing AID in the breast cancer cell lines is 36.4%. That study focused on the 
immunoglobulin variable (V) region gene analysis using well-defined breast cancer cell 
lines. In five of six identified V region genes, somatic mutations were apparent, for this 
somatic mutation there is an absolute requirement for AID enzyme expression. 
Interestingly, transcripts for AID were found constitutively in all six breast cancer lines 
examined at a level comparable with B-cell lymphoma. It has also been suggested that the 
aberrant mutations and genomic instability associated with aberrant AID expression. These 
findings suggested that AID expression in breast cancer cells could be a tumor-associated 
feature and essential for mutational and switch activity (Babbage et al., 2006). 
Another recent study applied Real-time RT-PCR for 151 breast cancer cell lines, the results 
confirmed that AID is expressed in ER+ and ER− breast cancer, as well as in the majority 
of the examined breast cancer cell lines. AID has an important role as a regulator of ER-
mediated gene expression in BC (Periyasamy et al., 2015).  
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Recent whole-genome sequencing of breast cancer has yielded genome-wide mutational 
signatures, one of which is consistent with the DNA mutation profiles associated with 
cystidine deamination. AID expression is frequently elevated in breast and other cancers, it 
can promote C-to-T mutations in breast cancer cells, these findings has led to AID 
overexpression in breast cancer could aid tumor initiation and progression by driving 
somatic mutations in cancer. Other studies showed that cystidine deamination is likely 
responsible for the breast cancer hypermutation (Periyasamy et al., 2015; Taylor et al., 
2013).  
Several studies have shown that AID overexpression can induce DNA damage responses 
resulting in the appearance of classical markers such as double-stranded breaks, and 
elevated levels of mutation (Harris, 2015).  In our study to explain the tumorigenic activity 
of AID among these patients, further studies are still needed to examine the up regulation 
of AID and its tumorigenic effect inducing mutations in tumor suppressor genes and 
oncogenes. The transcriptional regulatory elements for AID have been localized to four 
regions, there are conserved binding sites for at least 19 transcription factors within these 
regions, both activating and repressive factors. Activating factors such as NF- κ B, Stat6, 
CREB, E2A , Pax5 and HoxC4 are known to regulate the AID gene locus by binding to 
AID promoter causing AID transcription induction (Rebhandl et al., 2015; Park, 2012; 
Stavnezer, 2011). Recent studies showed that NF-KappaB is constitutively activated in a 
variety of solid tumors including breast, prostate, lung, cervical, and pancreatic cancer (Wu 
et al., 2015; Chen et al., 2012). Several proinflammatory cytokines, including TNF-  and 
IL-1 , play important roles in the pathophysiology of chronic inflammatory disease. AID 
expression is strongly induced in response to proinflammatory cytokine stimulation via 
NF-κB activation (Hoesel and Schmid, 2013; Endo et al., 2007), leading to mutations on 
oncogenes such as KRAS and cMyc (Sawai et al., 2015). 
Steroid hormones like estrogen are thought to be oncogenic for breast. It can influence the 
development and growth of the majority of breast carcinomas through their binding to 
steroid hormone receptors estrogen receptor ER (Karamouzis et al., 2011). Estrogen-
estrogen receptor complexes directly bind to the AID promoter and enhance AID 
transcription, leading to AID expression induction. However, other studies suggested that 
estrogen-estrogen receptor complexes directly bind to the HoxC4 promoter, and not to the 
AID promoter. Activating HoxC4 transcription leads to induce AID expression in response 
to inflammations and infections (Orthwein and Noia, 2012; Park, 2012). Estrogen induced 
AID expression by >20 fold, therefore we can suggest that estrogen-induced autoimmunity 
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and oncogenesis may be caused by AID as a DNA instability factor (Pauklin et al., 2009). 
Estrogen mediating genome instability via the activation of AID may provide a novel 
molecular mechanism that is important for breast cancer pathology (Pauklin et al., 2009; 
Mechtcheriakova et al., 2012).  
 
Chronic inflammation also leads to aberrant AID expression and increase AID expression 
which contributes to cancer development by inducing genetic alterations in epithelial cells. 
The development of hepatocellular carcinoma (HCC) caused by hepatitis virus infection 
and gastric cancer caused by H. pylori infection, are representative examples of 
inflammation-associated carcinogenesis. Inflammation pathophysiology is associated with 
the transcriptional factor NF-κB which is activated by various proinflammatory cytokines, 
such as tumor necrosis factor (TNF)-α, and viral/bacterial infection. Recent studies 
indicated that the mutagenic activity of AID may cause inflammation-associated 
carcinogenesis in various tissues (Takai et al., 2011; Shimizo et al., 2012). Other studies 
provide strong evidence that the inflammation-induced AID expression is required for 
epithelial to mesenchymal transition (EMT) in breast cancer cells. EMT is a process by 
which epithelial cells lose their cell polarity and cell-cell adhesion, and gain invasive 
properties allowing them to migrate easily (Rebhandl et al., 2015). 
Women who are exposed to some sources of environmental pollution such as pesticides, 
fertilizers, dusts are at higher risk of breast cancer. Environmental pollution is a major 
cause of chronic inflammation; exposure occurs at certain workplaces and in the general 
population from foods. One of the environmental pollutant is known as Cd (the Ames-
negative carcinogen). Cd has been shown to induce AID gene expression in somatic cells 
via the activation of NF-κB.  It is reported that Cd activates NF-κB and also estrogen 
receptor ER which enhances AID transcription as we mentioned before (Tatemishi et al., 
2014). 
Aberrant expression of AID in autoimmune diseases causes the somatic mutations and 
dysfunction of tumor suppressor genes like TP53. Several studies showed that AID was 
up-regulated in non-lymphoid tumor cells such as breast cancer, cholangiocarcinoma, 
hepatoma and colorectal cancer cells (Takai et al., 2009). Moreover, the somatic mutations 
of TP53 found in these cancer cells appeared to be a direct target of AID. These studies 
suggest a possible mechanism by which the aberrant expression of AID induces somatic 
mutations in TP53, leading to tumor formation (Igarashi et al., 2010). 
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Infections with some bacteria and viruses play a role in developing cancer, one of their 
mechanisms is by increasing AID expression. Helicobacter pylori, a class 1 carcinogen for 
human gastric cancer, affects AID expression, thereby contributing to the accumulation of 
mutations in tumor-related genes. Aberrant AID activity may therefore be a novel link 
between infection and carcinogenesis (Marusawa and Chiba, 2010). Some viruses, 
especially human papilloma virus HPV, have been suspected to play an etiological role in 
breast cancer. Many molecular studies indicated that HPV DNA is present at a high 
frequency in BC samples but is rare in normal breast tissues. HPV could trigger aberrant 
expression of AID in breast epithelial cells which results in genomic instability and 
mutations in TP53 tumor suppressor gene (Matsumoto et al., 2007; Nagata et al., 2014; 
Ohba et al., 2014).  
This study highlighted the importance of the DNA editor, AID, in the cellular events 
leading to genetic mutations during the development of breast cancers. We demonstrated 
for the first time that aberrant AID protein expression is found in BC cells in Palestinian 
patients in agreement with other studies. It is the first study done in Palestine and 
worldwide to examine the AID protein expression in breast cancer tissues by IHC 
technique. Here, a possible suggestion for AID activation in these BC cases is that estrogen 
my binding of estrogen receptor on AID promoter and induces its expression, since we 
found that most AID positive cases are estrogen receptor positive.  
The limitations of this study  is there is a small number of BC cases to work with and the 
lack of clinical data for some patients like the hormone receptor status, and fresh tissue 
samples were not available, so cooperation  with researchers and the hospitals is of great 
importance    
In summary, AID may represent a new marker for breast cancer. AID inhibition may 
decrease the rate of tumor evolution and stabilize the targets of existing therapeutics 
(Burns et al., 2013). In this study possible suggestion for AID activation in these BC cases 
is that estrogen may induce AID expression by binding to its promoter and enhancing its 
transcription, leading to AID expression induction. Inflammation  may also play an 
important role in activating AID and contributing to BC development through NF-κB 
pathway. Activated AID induces mutations in tumor suppressor genes and oncogenes. So 
AID could provide genetic fuel for cancer development and metastasis. AID may be a 
prime therapeutic target because it is rarely expressed in most normal tissues, and it is a 
dominant-acting enzyme with an active site that may be druggable (Harris, 2015). Further 
studies are needed to verify this hypothesis. 
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In conclusion, our findings showed that aberrant AID expression may be involved in some 
BC patients. No correlation was detected between AID expression and age, tumor stage or 
tumor grade. AID may have a diagnostic and prognostic utility in the future. More studies 
are needed to examine AID induction, regulation and mechanism of action within BC. 
Further studies are required to examine whether the elevated levels of AID could 
contribute to the development of metastases in BC. 
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4.2 Recommendations 
Little is known and much remains to be learned about the molecular identification and 
mechanism of induction of AID in breast cancer. To support our results, further molecular 
studies on AID expression using large scales of BC patients (100 cases or more) are 
needed. 
In Palestine, many obstacles are existed in the research field including: the difficulty of 
having fresh tissue from patients to apply different molecular techniques such as RT-PCR 
and western blot. Moreover, the lack of clinical data in the patients files which makes the 
statistical analysis of the obtained data for clinical research inadequate. Joint cooperation 
between researchers, hospitals and pathologists are recommended. 
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